French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Feb 27, 2024

Keywords

ClinConnect Summary

The FRENCH.MRD.PDAC trial is studying a type of blood test called a liquid biopsy to see if it can help doctors predict the risk of pancreatic cancer returning after treatment. Specifically, researchers want to find out if detecting tiny pieces of cancer DNA (called ctDNA) in the blood after surgery and chemotherapy can identify patients who are more likely to have their cancer come back. This trial is part of a larger European study aimed at improving care for patients with pancreatic cancer.

To participate in this trial, individuals must be 18 years or older and have been diagnosed with a specific type of pancreatic cancer called pancreatic ductal adenocarcinoma. They should be scheduled for surgery intended to completely remove the cancer. Unfortunately, people with certain conditions, like hereditary pancreatic cancer or other active cancers, cannot join. Participants will undergo blood tests to check for ctDNA and will be monitored over time to see how they respond to treatment. This research could lead to better ways to manage and follow up on patients after their cancer treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pancreatic ductal adenocarcinoma, according to the assessment of the MDT.
• • Age 18 years or older.
• • Scheduled for curative intent surgical resection.
• Exclusion Criteria:
• • Hereditary pancreatic cancer.
• • Verified distant metastases.
• • Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and/or otherwise considered by the Investigator to be unlikely to complete the study.
• • Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening.
• • Pregnant or nursing woman, or in childbearing age and not willing to use contraception
• • Adult subject to a legal protection
• • Not covered by Health insurance
• • Patient unable to understand and sign written informed consent.